Why Sagimet Biosciences Stock Is Soaring Today [Globe and Mail, The (Toronto, Canada)]
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: Globe and Mail, The
Its flagship acne drug denifanstat has performed well in Phase 3 trials in China, and certainly well enough in Phase 2 testing in the United States. Although the company will soon dilute existing shareholders' stakes by issuing new shares, the fundraising will support an opportunity that's well worth it. Investors had every reason to suspect today's news from Sagimet Biosciences (NASDAQ: SGMT) was coming sooner or later. Nevertheless, seeing the official announcement has clearly proven inspiring. As of 11:40 a.m. ET Monday, SGMT shares are up a hefty 45.2%, reaching a high last seen in November. The news? Following a successful Phase 3 trial in China, the biopharma company now plans to initiate Phase 3 trials of its acne-fighting denifanstat in the United States. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continu
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences (SGMT) had its price target lowered by Guggenheim from $27.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans [Yahoo! Finance]Yahoo! Finance
- Why Sagimet Biosciences Stock Is Soaring Today [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockGlobeNewswire
- Sagimet Biosciences Provides Strategic and Corporate Updates [Yahoo! Finance]Yahoo! Finance
SGMT
Earnings
- 3/11/26 - Beat
SGMT
Sec Filings
- 4/28/26 - Form 8-K
- 4/28/26 - Form 424B5
- 4/27/26 - Form 8-K
- SGMT's page on the SEC website